Stockreport

InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting

InflaRx N.V.  (IFRX) 
Last inflarx n.v. earnings: 8/14 04:05 pm Check Earnings Report
PDF JENA, Germany, March 18, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the c [Read more]